Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer

Схожие документы

• Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
  по: Narek Shaverdian, MD, и др.
  Опубликовано: (2021-07-01)
• Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study
  по: Chloe Ahryung Lim, и др.
  Опубликовано: (2023-12-01)
• High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
  по: Ciani Ellison, MD, и др.
  Опубликовано: (2024-12-01)
• A Radiomics-Based Machine Learning Model for Predicting Pneumonitis During Durvalumab Treatment in Locally Advanced NSCLC
  по: Takeshi Masuda, и др.
  Опубликовано: (2026-01-01)
• Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
  по: Yuhei Kinehara, MD, PhD, и др.
  Опубликовано: (2023-11-01)